Dominic Ferrey, MD
Clinical Neurophysiology · San Diego, CANPI 1548603186
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,268 of the $10,809 with a category attached, or 67.2%. 11 manufacturers reported payments, led by AstraZeneca at 57.4% of the total. 2025 is the largest year on record at $5,589, more than ten times the $254 reported in 2019.
Across 46 payments — averaging $234.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$6K
- Takeda Pharmaceuticals U.S.A., Inc.$3K
- Argenx US, Inc.$1K
- Biogen$281
- Tanabe Pharma America, Inc.$151
- UCB, Inc.$150
- plus $296 from 5 others
Across 43 payments — averaging $5659.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi$149K
- Takeda Pharmaceuticals U.S.A., Inc.$70K
- Alnylam Pharmaceuticals Inc.$24K
What the payments were for
- Consulting fees$7,26867%
- Travel & lodging$1,82717%
- Food & beverage$1,68316%
- Education$300%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 13 | $6,203 |
| Takeda Pharmaceuticals U.S.A., Inc. | 17 | $2,541 |
| Argenx US, Inc. | 1 | $1,188 |
| Biogen | 3 | $281 |
| Tanabe Pharma America, Inc. | 5 | $151 |
| UCB, Inc. | 1 | $150 |
| Alnylam Pharmaceuticals Inc. | 1 | $122 |
| Ionis Pharmaceuticals, Inc. | 1 | $100 |
| CSL Behring | 2 | $39 |
| EDW Pharma, Inc. | 1 | $20 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$10,809 in reported general payments places this provider in the 75th percentile of 49 clinical neurophysiology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 53 | $665,284 |
| NuedextaDextromethorphan Hbr/Quinidine | 11 | $16,276 |
| Mycophenolate Mofetil | 16 | $3,746 |
| Pyridostigmine Bromide | 19 | $1,966 |
| Gabapentin | 39 | $1,635 |
| Ropinirole Hcl | 13 | $1,112 |
| Riluzole | 12 | $641 |
| Baclofen | 17 | $552 |
| Duloxetine Hcl | 15 | $511 |
| Pregabalin | 20 | $440 |
| Prednisone | 18 | $193 |
| Diazepam | 13 | $78 |
| Alprazolam | 12 | $15 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in San Diego
- Alisherhon AzamovSan Diego$260
- Jeffrey GertschSan Diego$144
- William ShihSan Diego$20
- Said BeydounLos Angeles$985K
- Christopher LockStanford$159K
- Srikanth MuppidiStanford$150K
- Mitchell MiglisStanford$51K
- Michael AminoffSan Francisco$41K
- Safwan JaradehStanford$34K
- Sadiq AltamimiPomona$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.